Current Clinical Trials

Current Clinical Trials

Clinical trials are experiments that test whether a new compound is both safe for human use and effective for treatment of the disease it is being evaluated for. For individuals with a neurodgenerative form of dementia (any form) there are curently no effective disease-modifying treatments, and even existing symptomatic therapies are very weak. Without MANY volunteers who are willing to take the risk of exposure to an incompletely-tested agent, we will never achieve the aim of slowing, stopping, or reversing the effects of these disease.

If you are eligible to participate, please consider volunteering.

Phase 3 Study of LY3314814

For individuals with mild Alzheimer's disease and Mini Mental State score of 20-26.

The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia. This is a phase 3 study which is a clinical trial that gathers more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. LY3314814 is a brain-permeable inhibitor of human Beta-site amyloid precursor protein-cleaving enyzme I (or BACE 1/Beta-secretase). The study is seeking to slow the progression of disease in patients with early Alzheimer's disease.

Phase 3 Study of AVP-786

Eligible participants for this study must have a diagnosis of probable AD and must have clinically meaningful agitation secondary to AD.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo for the treatment of agitation in patients with dementia of the Alzheimer's type. Patients are enrolled for approximately 16 weeks with up to 4 weeks for the screening period and 12 weeks of treatment (either placebo or AVP-786). At the conclusion of this study, patients are offered to continue in the next phase of the study to evaluate the long-term safety and maintenance of efficacy for AVP-786. The length is approximately 56 weeks and all patients are on varying blinded doses of AVP-786. In the United States, there are currently no approved treatments for patients with agitation with dementia of the Alzheimer's type.

Healthy Seniors for Brain Imaging Studies

We are always looking for participants over age 70 to serve as comparison groups for our Alzheimer’s patient sample. You must be able to get an MRI scan (no claustrophobia, no pacemaker or cardiac stent, no metal in the head, neck or eyes). The purpose of these studies is to improve understanding of how changes in the brains of those with Alzheimer’s disease and those with mild memory and thinking impairments are related to behavioral changes.

The study involves two components, and takes place on campus, in the Clinical Center/Radiology complex on Service Road. First, you will be asked to answer questions that assess thinking abilities. Participants without cognitive impairment will also be asked to identify themselves in photographs and will partake in measurement of behavioral responses to various levels of minor discomfort (forearm pressure). This component of the study takes 20-40 minutes.

The second part of the study lasts for about an hour and involves an MRI scan of the brain (NO radiation or injections are involved). During part of the scanning, participants with no memory or thinking impairments will view pictures of faces followed by laying in the scanner at rest. Those participants with mild memory and thinking impairments will only lie in the scanner at rest. After scanning, you will also have a blood draw for genetic testing (a single vial). You will be paid $20 for completing the study.

If you are interested in participating and are a senior with no memory impairment, please contact Paul Beach at (269) 251-0027 or If you believe you may have some memory or other thinking impairments and wish to participate, please contact Ashley Hannah at (216) 370-1900 or

For each study, please click here to obtain more information about eligibility criteria, study logistics and scheduling an appointment for screening.

Developed by DECS | Contact Information | Privacy Statement | Site Accessibility

MSU is an affirmative action, equal opportunity employer

© Michigan State University Board of Trustees, East Lansing, MI 48824